Agios Pharmaceuticals (AGIO) has moved into a new phase with mitapivat, submitting a supplemental New Drug Application for accelerated FDA approval in sickle cell disease and preparing to showcase detailed trial data at the European Hematology Association Congress.

Despite the regulatory momentum around mitapivat and a series of recent healthcare conference appearances, Agios’s share price shows mixed signals, with a 30 day share price return of 5.28% but a 1 year total shareholder return that declined 5.35%. This suggests only modest overall momentum so far.

If advances in rare disease treatments interest you, this could be a good moment to scan the market for other healthcare names shaping the future of medicine through 30 healthcare AI stocks

With Agios trading at $28.50, carrying a low value score of 2 and sitting at a steep intrinsic discount, investors now face a key question: is this a genuine opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 30.7% Undervalued

Agios’s most followed valuation narrative places fair value at $41.13 versus the last close at $28.50, framing a sizable gap that hinges on pipeline execution and future profitability.

Upcoming potential FDA approval and commercial launch of PYRUKYND for thalassemia in the U.S. is set to significantly expand Agios' addressable market, driven by the high rate of disease diagnosis through newborn screening and well-defined patient populations, which should lift revenue growth in coming years.

Curious what justifies that valuation gap on a loss making company? The narrative leans heavily on rapid revenue expansion, richer margins and a premium future earnings multiple.

Result: Fair Value of $41.13 (UNDERVALUED)

However, investors also need to weigh the heavy reliance on PYRUKYND and ongoing high R&D and SG&A spending, which could keep profitability under pressure.

Another View: Rich Sales Multiple Raises the Bar

While the SWS model suggests Agios is trading below fair value, the stock tells a different story on sales-based metrics. At a P/S of 25.7x versus 10.2x for the US Biotechs industry and 2.7x for peers, with a fair ratio of 0x, the current price reflects a significant level of optimism. Is that premium something you are comfortable paying?

To see how the current pricing compares with the underlying numbers, take a closer look at the detailed valuation breakdown through See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals across valuation and sentiment, what matters most is how you interpret the trade off between risks and rewards. Take a closer look at the balance of 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Agios is on your radar, do not stop there; broaden your watchlist now so you are not looking back wishing you had checked other opportunities.

• Spot resilient potential by scanning 67 resilient stocks with low risk scores that may help you keep portfolio volatility in check.
• Hunt for mispriced quality using the screener containing 21 high quality undiscovered gems that focus on companies with strong fundamentals flying under most radars.
• Strengthen your core holdings by reviewing the solid balance sheet and fundamentals stocks screener (46 results) and focus on companies with financial foundations built to endure.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.